IDEC Y2B8 RADIOIMMUNOTHERAPY FOR NON HODGKINS LYMPHOMA AFTER RITUXIMAB

钇标记的IDEC抗CD20鼠单抗(IDEC-Y2B8)与嵌合的IgG1 kappa抗CD20单抗Rituxan正在研究中，用于治疗复发或难治性B细胞性非霍奇金淋巴瘤(NHL)。这项试验的目标是：1)确定IDEC-Y2B8疗法对复发或难治、低级别、滤泡性或转化的B细胞性非霍奇金淋巴瘤患者的疗效，这些患者对以前的利妥昔单治疗无效(PR或CR)。主要疗效变量将是总应答率，次要疗效变量将是有效时间和进展时间，其他分析将包括完全、临床完全和部分应答率以及下一次抗癌治疗的时间，以及2)表征IDEC-Y2B8作为治疗剂和IDEC-IN2B8作为显像剂与Rituxan联合使用时的安全性(不良事件)。

Yttrium-labeled IDEC anti-CD20 murine monoclonal antibody (IDEC-Y2B8) in combination with the chimeric IgG1 kappa anti-CD20 monoclonal antibody Rituxan is under investigation for treatment of patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). The objectives of this trial are: 1) to determine the efficacy of IDEC-Y2B8 therapy in patients with relapsed or refractory, low grade or follicular or transformed B-cell non-Hodgkin's lymphoma whose disease did not respond (did not achieve a Pr or CR) to previous treatment with Rituxan. The primary efficacy variable will be overall response rate, secondary efficacy variables will be duration of response and time to progression, and additional analyses will include complete, clinical complete and partial response rate, and time to next anti-cancer treatment and 2) to characterize (qualitative, quantitative, duration and reversibility) the safety (adverse events) of both IDEC-Y2B8 as a therapeutic agent and IDEC-In2B8 as an imaging agent when administered in conjunction with Rituxan.